Product Overview
[Drug name]
Generic name: Terazosin hydrochloride capsules
Trade name: PaiSu Terazosin hydrochloride capsules 2mg*24 tablets
Pinyin full code: PaiSuYanSuanTeLaZuoZuoJiaoNang 2mg*24Li
[Main ingredients]
The main ingredient of this product is terazosin hydrochloride.
[Properties]
This product is a hard capsule, and its contents are white or off-white granules or powder.
[Indications/Main Functions]
For the treatment of hypertension, it can be used alone or in combination with other antihypertensive drugs. It is used to improve the urination symptoms of patients with benign prostatic hyperplasia. Such as frequent urination, urgent urination, thinning urine stream, dysuria, increased nocturia, feeling of incomplete urination, etc.
[Specifications]
2mg*24 tablets
[Usage and Dosage]
Oral. Once a day, take before bedtime for the first time. The starting dose is 1mg. If you need to restart treatment after stopping the drug, you must also start with 1mg and gradually increase the dose.
[Adverse Reactions]
The main adverse reactions of this product are: headache, dizziness, weakness, palpitations, nausea, postural hypotension, etc. These reactions are usually mild and can disappear on their own with continued treatment. If necessary, the dose can be reduced.
[Contraindications]
Contraindicated for those who are allergic to this product.
[Drug Interactions]
In controlled trials, terazosin was added to diuretics and certain b-adrenergic blockers, and no unexpected interactions were observed. Terazosin has been co-administered with the following types of drugs: analgesics/anti-inflammatory drugs, antibiotics, anticholinergic/sympathomimetic drugs, antigout drugs, cardiovascular drugs, corticosteroids, gastrointestinal drugs, hypoglycemic drugs, sedatives and tranquilizers. When terazosin and verapamil are co-administered with other drugs, the mean AUC0-24 of terazosin increases by 11% when verapamil is first administered and by 24% after 3 weeks of treatment with verapamil, and at this time the mean Tmax of terazosin decreases from 1.3 hours to 0.8 hours. No significant effect on verapamil was found. When terazosin and captopril are co-administered to steady state, the maximum plasma concentration of terazosin increases linearly with dose.
[Precautions]
Use with caution in pregnant and lactating women. Patients should avoid sudden changes in posture or actions that may cause dizziness or fatigue when starting and increasing the dose.
[Use in children]
Not yet clear.
[Use in elderly patients]
Not yet clear.
[Overdose]
Not yet clear.
[Pharmacology and Toxicology]
This product is a selective α1 receptor blocker that can reduce peripheral vascular resistance and has a lowering effect on both systolic and diastolic blood pressure. It is usually not accompanied by tachycardia, has no adverse effects on electrolytes, blood sugar, liver and kidney function, and has a certain improvement effect on blood lipids. It can selectively block the smooth muscle α1 receptors in the bladder neck, prostate gland and capsule, thereby reducing smooth muscle tension, reducing lower urinary tract resistance, and relieving symptoms such as frequent urination, urgency, and dysuria caused by prostate hyperplasia.
